Verrica Pharmaceuticals, Inc.

How big is Verrica Pharmaceuticals, Inc.?

As of Jun 18, Verrica Pharmaceuticals, Inc. has a market capitalization of 59.40 million and reported net sales of 7.18 million with a net profit of -65.99 million over the latest four quarters. Shareholder's funds are at -9.86 million, and total assets amount to 54.62 million.

As of Jun 18, Verrica Pharmaceuticals, Inc. has a market capitalization of 59.40 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 7.18 million, while the sum of net profit for the same period is -65.99 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -9.86 million, and the total assets amount to 54.62 million.

What does Verrica Pharmaceuticals, Inc. do?

Verrica Pharmaceuticals, Inc. is a clinical-stage medical dermatology company focused on developing treatments for skin diseases. As of March 2025, it reported net sales of $3 million and a net loss of $10 million, with a market cap of $59.40 million.

Overview:<BR>Verrica Pharmaceuticals, Inc. is a clinical-stage medical dermatology company focused on developing pharmaceutical products for the treatment of skin diseases with unmet needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 59.40 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.63 <BR>Return on Equity: 337.21% <BR>Price to Book: -3.20<BR><BR>Contact Details:<BR>Address: 10 N High St Ste 200, WEST CHESTER PA: 19380-3014 <BR>Tel: 1 484 4533300 <BR>Website: http://www.verrica.com/

Should I buy, sell or hold Verrica Pharmaceuticals, Inc.?

Who are in the management team of Verrica Pharmaceuticals, Inc.?

As of March 2022, the management team of Verrica Pharmaceuticals, Inc. includes Chairman Paul Manning, CEO Ted White, and Directors Lawrence Eichenfield, Diem Nguyen, Sean Stalfort, Craig Ballaron, and Mark Prygocki. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Verrica Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Paul Manning, Chairman of the Board<BR>- Mr. Ted White, President, Chief Executive Officer, and Director<BR>- Dr. Lawrence Eichenfield, Director<BR>- Dr. Diem Nguyen, Director<BR>- Mr. Sean Stalfort, Director<BR>- Mr. Craig Ballaron, Independent Director<BR>- Mr. Mark Prygocki, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Verrica Pharmaceuticals, Inc. overvalued or undervalued?

As of November 7, 2022, Verrica Pharmaceuticals is considered risky and overvalued, with unfavorable financial metrics and a one-year stock return of -78.16%, significantly underperforming the S&P 500's 17.14%.

As of 7 November 2022, Verrica Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -3.05, an EV to EBIT of -1.25, and an EV to EBITDA of -1.28, indicating significant negative valuations compared to traditional benchmarks.<BR><BR>In comparison to peers, Verrica's valuation ratios are less favorable, with Gossamer Bio, Inc. showing a P/E of -4.3771 and an EV to EBITDA of -4.1514, while Rigel Pharmaceuticals, Inc. is very attractive with a P/E of 7.4943 and an EV to EBITDA of 6.4016. The stark contrast in these ratios highlights Verrica's challenging position within the industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a one-year return of -78.16% compared to the index's 17.14%, reinforcing the view of overvaluation.

Is Verrica Pharmaceuticals, Inc. technically bullish or bearish?

As of September 9, 2025, Verrica Pharmaceuticals, Inc. has a mildly bullish trend overall, supported by a bullish monthly RSI, but faces bearish signals from daily moving averages and other indicators, while significantly underperforming the S&P 500 with a 1-year return of -78.16%.

As of 9 September 2025, the technical trend for Verrica Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a mildly bullish MACD on both weekly and monthly time frames, and a bullish monthly RSI. However, the daily moving averages are bearish, and both the Bollinger Bands and KST indicators are bearish on a monthly basis. Additionally, the Dow Theory shows a mildly bearish stance on both weekly and monthly time frames. <BR><BR>The stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a 1-year return of -78.16% versus the S&P 500's 17.14%.